Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Injury- and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa
Alexander Nyström, Leena Bruckner‐Tuderman
Matrix Biology (2018) Vol. 68-69, pp. 547-560
Closed Access | Times Cited: 60

Showing 26-50 of 60 citing articles:

Balance and circumstance: The renin angiotensin system in wound healing and fibrosis
Rocco Bernasconi, Alexander Nyström
Cellular Signalling (2018) Vol. 51, pp. 34-46
Closed Access | Times Cited: 26
MicroRNA‐145‐5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts
Angelo Giuseppe Condorelli, E. Logli, Francesca Cianfarani, et al.
British Journal of Dermatology (2019) Vol. 181, Iss. 5, pp. 1017-1027
Closed Access | Times Cited: 25
Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
Toini Pemmari, Larisa Ivanova, Ulrike May, et al.
Molecular Therapy (2020) Vol. 28, Iss. 8, pp. 1833-1845
Open Access | Times Cited: 22
Complexity of matrix phenotypes
Renato V. Iozzo, Achilleas D. Theocharis, Thomas Neill, et al.
Matrix Biology Plus (2020) Vol. 6-7, pp. 100038-100038
Open Access | Times Cited: 22
Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index
Nicholas H. B. Schräder, Eva W H Korte, José C. Duipmans, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 24, pp. 5836-5836
Open Access | Times Cited: 17
Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa
Christine Gretzmeier, Didier Pin, Johannes S. Kern, et al.
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 4, pp. 1094-1102.e3
Open Access | Times Cited: 16
Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis
Esteban Chacón-Solano, Carlos León, Marta Carretero, et al.
Matrix Biology (2022) Vol. 111, pp. 189-206
Open Access | Times Cited: 12
Gamma-secretase inhibitors down-regulate the pro-fibrotic Notch signaling pathway in recessive dystrophic epidermolysis bullosa
Angelo Giuseppe Condorelli, Rebecca Nobili, A. Muglia, et al.
Journal of Investigative Dermatology (2024)
Closed Access | Times Cited: 2
Distinct contributions of meprins to skin regeneration after injury – Meprin α a physiological processer of pro-collagen VII
Daniel Kruppa, Florian Peters, Olivier Bornert, et al.
Matrix Biology Plus (2021) Vol. 11, pp. 100065-100065
Open Access | Times Cited: 13
Oleogel Formulations for the Topical Delivery of Betulin and Lupeol in Skin Injuries—Preparation, Physicochemical Characterization, and Pharmaco-Toxicological Evaluation
Ramona Parvanescu, Claudia Watz, Elena-Alina Moacă, et al.
Molecules (2021) Vol. 26, Iss. 14, pp. 4174-4174
Open Access | Times Cited: 13
Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa
V.I. Oldakovskiy, Nikolay N. Murashkin, Maksim Lokhmatov, et al.
Journal of Pediatric Surgery (2022) Vol. 58, Iss. 4, pp. 619-623
Closed Access | Times Cited: 9
STAT3 targeting in dystrophic epidermolysis bullosa
Venugopal R. Mittapalli, Tobias Kühl, Sanya-Eduarda Kužet, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 5, pp. 1279-1281
Open Access | Times Cited: 13
Pharmaceutical Development of Film-Coated Mini-Tablets with Losartan Potassium for Epidermolysis Bullosa
Valentinë Elezaj, Ard Lura, Luis Canha, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 570-570
Open Access | Times Cited: 8
Is diet related to skin condition? A Mendelian randomization study
Qinyuan Wang, Zeming Qiu, Long Cheng, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Closed Access | Times Cited: 1
Skin Fragility: Perspectives on Evidence-based Therapies
Leena Bruckner‐Tuderman
Acta Dermato Venereologica (2020) Vol. 100, Iss. 5, pp. adv00053-101
Open Access | Times Cited: 10
A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy
Payal M. Patel, Virginia Jones, Christy Behnam, et al.
Antibodies (2021) Vol. 10, Iss. 2, pp. 19-19
Open Access | Times Cited: 9
Wound healing activity: A novel benefit of pyroligneous extract derived from pyrolytic palm kernel shell wood vinegar
Yongyuth Theapparat, Sunisa Khongthong, Natthrit Roekngam, et al.
Industrial Crops and Products (2022) Vol. 192, pp. 115994-115994
Closed Access | Times Cited: 6
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas
Julia Illmer, Roland Zauner, Josefina Piñón Hofbauer, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 1, pp. 80-93
Open Access | Times Cited: 3
Generation of a recessive dystrophic epidermolysis bullosa mouse model with patient-derived compound heterozygous mutations
Satoshi Takaki, Takashi Shimbo, Kentaro Ikegami, et al.
Laboratory Investigation (2022) Vol. 102, Iss. 6, pp. 574-580
Open Access | Times Cited: 5
Detection of Novel Biallelic Causative Variants in COL7A1 Gene by Whole-Exome Sequencing, Resulting in Congenital Recessive Dystrophic Epidermolysis Bullosa in Three Unrelated Families
Fozia Fozia, Rubina Nazli, May Alrashed, et al.
Diagnostics (2022) Vol. 12, Iss. 7, pp. 1525-1525
Open Access | Times Cited: 5
Challenges in the transfer and scale-up of mini-tableting: Case study with losartan potassium
Valentinë Lura, Stefan Klinken, Jörg Breitkreutz
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 192, pp. 161-173
Closed Access | Times Cited: 2
What do we learn from dystrophic epidermolysis bullosa, nails only? Idiopathic nail dystrophy may harbor a COL7A1 mutation as the underlying cause
Rui Yang, Yuanyuan Duan, Qingtao Kong, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 7, pp. 782-786
Closed Access | Times Cited: 5
Hereditary bullous diseases: current and innovative models to study the skin blistering disease epidermolysis bullosa
Christina Guttmann‐Gruber, Johann Bauer, Josefina Piñón Hofbauer
Drug Discovery Today Disease Models (2020) Vol. 32, pp. 17-25
Open Access | Times Cited: 5
Research in practice: Towards deciphering the role of epidermal proteases in recessive dystrophic epidermolysis bullosa progression
Pauline Nauroy, Eleni Zingkou, Georgia Sotiropoulou, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 6, pp. 828-832
Closed Access | Times Cited: 5
Increased abundance of Cbl E3 ligases alters PDGFR signaling in recessive dystrophic epidermolysis bullosa
Esther Martínez-Martínez, Regine C. Tölle, Julia Donauer, et al.
Matrix Biology (2021) Vol. 103-104, pp. 58-73
Open Access | Times Cited: 4

Scroll to top